KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Randomized phase III Study of Adding Paclitaxel to Chemoradiotherapy With Capecitabine and Mitomycin C in Squamous Cell Anal Carcinoma.Clin Colorectal Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41688329无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.Lancet Infect Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:森林图/亚组分析图;Figure 3:非 KM 图。PMID 41690325PMC132159742026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41690366无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41720427无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.Ann Surg OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41739398无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.Ann Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41780642无 PMCID2026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Soticlestat as an adjunctive therapy in children and young adults with Dravet syndrome.Epilepsia疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:研究设计图;FIGURE 2:CONSORT/入组流程图;FIGURE 3:森林图/亚组分析图;FIGURE 4:生活质量量表图。PMID 41784472PMC132852532026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.GastroenterologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41790076无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.J Pediatr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41796854无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial.J Thorac Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41796863无 PMCID2026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Long‑term outcomes of prophylactic cranial irradiation in high‑risk metastatic NSCLC: Final PRoT‑BM analysis.Radiother Oncol入排复审未纳入:The study is a Phase II randomized trial with a non-drug intervention (prophylactic cranial irradiation) and time-to-event endpoints. It is excluded based on the required phase (III/IIIb) and drug intervention criteria.PMID 41831620无 PMCID2026-Jun0.90The study is a Phase II randomized trial with a non-drug intervention (prophylactic cranial irradiation) and time-to-event endpoints. It is excluded based on the required phase (III/IIIb) and drug intervention criteria.无 KM 图
Efficacy and safety of brexpiprazole in early-episode schizophrenia: post hoc analysis of Phase 3 clinical trials in adults and adolescents.Psychiatry ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41849920无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial.Diabetes Obes Metab疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:AI 判定为 other。PMID 41883295PMC131461612026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.Nat MedPMID 41896648PMC132789492026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.BJU IntPMID 41896701PMC131689172026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41903611无 PMCID2026-Jun0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.J Allergy Clin Immunol PractPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41903881无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT.Radiother Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41905637无 PMCID2026-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Effectiveness of Four-Factor Prothrombin Complex Concentrate Versus Plasma in Patients on Vitamin K Antagonists Undergoing Urgent Orthopedic Surgery: A Post Hoc Analysis.Adv Ther入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41910938PMC132223262026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Phase III Prospective Randomised Study of Netarsudil and Concomitant Latanoprost Efficacy and Safety for Primary Open-Angle Glaucoma or Ocular Hypertension in Japan: J-ROCKET-2.Adv Ther已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。PMID 41915113PMC132223052026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.Nat MedPMID 41917160PMC132789672026-Jun0.98未发现恶性肿瘤人群证据。已完成
Effect of ivarmacitinib on patient-reported outcomes in patients with moderate-to-severe active rheumatoid arthritis: a post-hoc analysis of a phase III trial.Clin RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41922627无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
New conversations in an old argument: Lessons learnt from the PIONEER randomised feasibility study in resectable stage III-N2 NSCLC.Lung Cancer入排复审未纳入:The record describes a randomized feasibility study for a future Phase III trial, but it is not itself a definitive Phase III trial. The primary outcomes are feasibility and quality of life, not a time-to-event efficacy endpoint. No specific drug-containing intervention is part of the randomized comparison.PMID 41930542无 PMCID2026-Jun0.85The record describes a randomized feasibility study for a future Phase III trial, but it is not itself a definitive Phase III trial. The primary outcomes are feasibility and quality of life, not a time-to-event efficacy endpoint. No specific drug-containing intervention is part of the randomized comparison.无 KM 图
Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial.Lancet Gastroenterol Hepatol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41932350无 PMCID2026-Jun0.95Study meets criteria for oncology, human, randomized, Phase III, time-to-event endpoint, and original result report. However, it is ineligible because the intervention does not involve a drug; it compares two surgical procedures. Drug intervention is a required criterion and is explicitly absent.无 KM 图
Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials.Eur J Pharm BiopharmPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41935547无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Extended-Release Clonidine Hydrochloride for Attention Deficit Hyperactivity Disorder in Chinese Children and Adolescents: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.J Child Adolesc PsychopharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41944053无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.Adv Ther已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 flow diagram。PMID 41954860PMC132222332026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.J Child Adolesc PsychopharmacolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41958186无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Promising efficacy of coenzyme Q10 supplementation as adjunctive therapy in juvenile idiopathic arthritis: a randomized-controlled pilot study.Immunopharmacol Immunotoxicol入排复审未纳入:The study is not an oncology trial; it evaluates Coenzyme Q10 for juvenile idiopathic arthritis, which is a rheumatic/autoimmune condition. The primary efficacy endpoint is a non-time-to-event outcome (disease activity score), not OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis.PMID 41958203无 PMCID2026-Jun0.90The study is not an oncology trial; it evaluates Coenzyme Q10 for juvenile idiopathic arthritis, which is a rheumatic/autoimmune condition. The primary efficacy endpoint is a non-time-to-event outcome (disease activity score), not OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis.无 KM 图
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.Clin Lymphoma Myeloma LeukPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41986167无 PMCID2026-Jun0.95The record describes a secondary, exploratory analysis of patient-reported outcomes (chemotherapy-induced peripheral neuropathy and quality of life) from a Phase 3 randomized trial. While the trial itself is eligible (oncology, human, randomized, Phase 3, drug intervention), this specific report focuses on a quality-of-life/symptom endpoint, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). Therefore, it does not meet the eligibility criteria for the Kaplan-Meier digitization cohort.无 KM 图
Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41990300无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.J Parkinsons DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41995421无 PMCID2026-Jun0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。无 KM 图
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41996761无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer.Clin Oncol (R Coll Radiol)疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41996829无 PMCID2026-Jun0.95The report is a Phase III randomized trial with oncology and time-to-event endpoints, but the intervention is a radiation-based brachytherapy boost, not a systemic drug-containing therapy. Drug intervention is not explicitly established.无 KM 图
Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42000139无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Risk factors for aspiration pneumonia related to postoperative chemoradiotherapy for high-risk head and neck cancer: A supplementary analysis of a phase II/III JCOG1008 trial.Oral Oncol入排复审未纳入:This is a secondary/supplementary analysis of a Phase II/III randomized trial, focused on risk factors for a specific toxicity, not the primary efficacy report. It also lacks explicit evidence of a drug-containing intervention.PMID 42001583无 PMCID2026-Jun0.90This is a secondary/supplementary analysis of a Phase II/III randomized trial, focused on risk factors for a specific toxicity, not the primary efficacy report. It also lacks explicit evidence of a drug-containing intervention.无 KM 图
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.Lancet Diabetes EndocrinolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42009015无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension.Diabetes Res Clin PractPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42036072无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Identifying Symptom Clusters for Acute Dermatitis-Exploratory Analysis of a Randomized Control Trial Comparing Mepitel Film and Standard of Care for the Prevention of Radiation Dermatitis.Clin Breast CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42066679无 PMCID2026-Jun0.90The record describes a secondary analysis of a Phase III randomized controlled trial in human breast cancer patients. However, the reported outcomes (symptom clusters for radiation dermatitis) are patient-reported symptom/toxicity measures, not the survival, progression, recurrence, death, or time-to-event efficacy outcomes required for inclusion in the oncology survival cohort.无 KM 图
Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women - Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study.MaturitasPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42068869无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.J Infect入排复审未纳入:未发现恶性肿瘤人群证据。PMID 42070588无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.J Endocrinol Invest已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other。PMID 42082865PMC132191462026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.Circ Heart Fail已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 other。PMID 42104840PMC131602392026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI).Clin Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 42107198无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
FRUQUITAS trial: Study design of an ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma.Dig Liver DisAI 判定为临床试验方案/Protocol,尚非正式结果论文;因此未进入 KM Figure 抓取。PMID 42108156无 PMCID2026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.Neurol Clin PractPMID 42128444PMC131781462026-Jun0.98未发现恶性肿瘤人群证据。已完成
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.Lancet OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42134381无 PMCID2026-Jun0.90The record describes a Phase III randomized trial of breast radiotherapy schedules with a time-to-event primary endpoint (ipsilateral breast recurrence). However, the intervention is radiotherapy only, not a drug-containing intervention. Therefore, it does not meet the eligibility criterion for a drug-containing intervention.无 KM 图
Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 42150582无 PMCID2026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: results of a post-hoc analysis from the AReSVi-006 trial.EBioMedicine疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 flow diagram;Fig. 4:非 KM 图。PMID 42172919PMC132241232026-Jun0.98未发现恶性肿瘤人群证据。无 KM 图
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.ESMO Open已检查 1 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other。PMID 42202490PMC132354532026-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图